New five-year data show that Briumvi (ublituximab) provides sustained benefits for people with relapsing forms of MS, especially when started early. Results from the ULTIMATE clinical trials and their extension study found that most patients remained relapse-free, experienced low rates of disability progression, and in some cases saw improvements in disability over time. Relapse rates continued to decline with ongoing treatment, and no new safety concerns emerged during long-term follow-up. Researchers say these findings reinforce Briumvi’s role as a durable and well-tolerated treatment option for relapsing MS.
